![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1399705
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â±â ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2023-2032³â)Biotechnology Instruments Market - By Product (Analytical Instruments {Spectroscopy, PCR}, Lab Automation, Sequencing Instruments, Imaging Instruments), Application (Clinical Diagnostics, Proteomics & Genomics), End-user, Global Forecast, 2023-2032 |
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â±â ½ÃÀåÀº 2023-2032³â 4.4% ÀÌ»óÀÇ CAGRÀÌ Àü¸ÁµË´Ï´Ù.
÷´Ü ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡¿Í ¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¹ßȰ¡ ½ÃÀåÀ» Àü·Ê ¾ø´Â ¼ºÀåÀ¸·Î À̲ø°í ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ±â¼úÀÇ ¼ö¿ëÀº °úÇÐÀû ¹ß°ß°ú ÀÇÇÐÀû ºê·¹ÀÌÅ© ½º·ç Àü¸ÁÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î Waters CorporationÀº 2023³â 9¿ù¿¡ ³ª³ëÀÔÀÚ ºÐ¼®¿ë DynaPro ZetaStar Àåºñ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Àåºñ´Â Àü±â¿µµ¿ ±¤»ê¶õ ÃøÁ¤°ú ÇÔ²² µ¿Àû ¹× Á¤Àû ±¤»ê¶õ ÃøÁ¤À» ÇϳªÀÇ Àåºñ·Î °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÷´Ü ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â±â ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
½ÇÇè½Ç ÀÚµ¿È Àåºñ ºÎ¹®Àº 2032³â±îÁö ½ÃÀå¿¡¼ ¸·´ëÇÑ ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÚµ¿È´Â ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇϰí, Á¤È®µµ¸¦ ³ôÀ̰í, ½ÇÇèÀ» °¡¼ÓÈÇÏ¿© ½Ã°£°ú ºñ¿ëÀ» Àý°¨Çϰí ÀÖ½À´Ï´Ù. ¼¼°è ¿¬±¸¼Ò´Â »ùÇà 󸮿¡¼ µ¥ÀÌÅÍ ºÐ¼®¿¡ À̸£±â±îÁö ÀÚµ¿È ¼Ö·ç¼ÇÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¿¬±¸°³¹ßÀÇ È¿À²¼ºÀ» ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó ÀçÇö¼º°ú µ¥ÀÌÅÍ Á¤È®¼ºÀ» º¸ÀåÇÏ°í »ý¸í°øÇÐÀÇ È¹±âÀûÀÎ ¹ß°ßÀ» À§ÇÑ Åä´ë¸¦ ¸¶·ÃÇÕ´Ï´Ù.
´Ü¹éÁúüÇÐ ¹× À¯ÀüüÇÐ ºÐ¾ß´Â °úÇÐÀÚµéÀÌ ºÐÀÚ ¼öÁØ¿¡¼ »ý¸íÀÇ º¹À⼺À» ´õ ±íÀÌ ÆÄ°íµé¸é¼ 2032³â±îÁö ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÷´Ü »ý¸í°øÇÐ Àåºñ¸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº ´Ü¹éÁú°ú À¯ÀüÀÚ¸¦ Àü·Ê ¾ø´Â Á¤¹Ðµµ·Î ºÐ¼®ÇÏ¿© Áúº´, ÀǾàǰ °³¹ß ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ ¹× ´Ü¹éÁúüÇа¡ Á¤¹ÐÀÇ·áÀÇ ¹ßÀüÀ» °¡´ÉÇÏ°Ô ÇÏ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ ¿¬±¸¸¦ ÃËÁøÇÏ´Â ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â±â´Â ¼¼°è ½ÇÇè½Ç¿¡¼ ÇʼöÀûÀÎ Åø·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â±â ½ÃÀåÀº 2032³â±îÁö Ȱ¹ßÇÑ ¼ö¿ä¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±Þ¼ÓÇÑ °æÁ¦ ¼ºÀå, R&D ÅõÀÚ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ÀÌ Áö¿ª ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡µéÀº »ý¸í °øÇÐÀÇ Áøº¸¸¦ äÅÃÇÏ´Â ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±â¼ú Çõ½ÅÀ» ¹Þ¾ÆµéÀ̰í ÀÖÀ¸¸ç ½ÃÀå Àü¸ÁÀ» Çü¼ºÇÏ´Â Áß¿äÇÑ ÁøÀÔÀÚ°¡ µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.
The biotechnology instruments market is anticipated to observe more than 4.4% CAGR from 2023 to 2032. The increasing demand for advanced healthcare solutions, coupled with the rise in R&D activities, is steering the market towards unprecedented growth. The acceptance of cutting-edge technologies is redefining the landscape of scientific discovery and medical breakthroughs.
For instance, in September 2023, Waters Corporation launched the DynaPro ZetaStar instrument for nanoparticle analysis, which enables dynamic and static light scattering along with electrophoretic light scattering measurements in one device. An escalating demand for advanced healthcare solutions is propelling the market growth.
The biotechnology instruments market is classified by product, application, end-user, and region.
The lab automation instruments segment is predicted to generate massive revenues in the market by 2032. Automation is streamlining processes, enhancing precision, and accelerating experimentation, thereby reducing time and costs. Laboratories worldwide are adopting automated solutions for tasks ranging from sample handling to data analysis. This not only boosts the efficiency of R&D but also ensures reproducibility and data accuracy, laying the foundation for groundbreaking discoveries in biotechnology.
The proteomics and genomics segment will drive the market growth through 2032 as scientists delve deeper into the intricacies of life at the molecular level. Advanced biotechnology instruments enable researchers to analyze proteins and genes with unprecedented accuracy, providing insights into diseases, drug development, and personalized medicine. As genomics and proteomics enable the advancements of precision medicine, the biotechnology instruments facilitating these studies are becoming indispensable tools in laboratories worldwide.
Asia Pacific biotechnology instruments market is expected to record strong demand through 2032. Rapid economic growth, increased investment in R&D, and a growing focus on healthcare infrastructure are driving the market in this region. Countries like China, Japan, and India are at the forefront of adopting biotechnological advancements. As the Asia Pacific region embraces innovation, it is poised to become a key player in shaping the market outlook.